CD19 and acute lymphoblastic leukemia: CAR T-cells targeting CD19 (KymriahTM and YescartaTM) are the first cell-based therapies to be approved by the United States Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma, respectively.